KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Non Operating Income (2020 - 2025)

Recursion Pharmaceuticals' Non Operating Income history spans 6 years, with the latest figure at $232000.0 for Q4 2025.

  • For Q4 2025, Non Operating Income fell 95.24% year-over-year to $232000.0; the TTM value through Dec 2025 reached $3.2 million, down 77.23%, while the annual FY2025 figure was $3.2 million, 77.23% down from the prior year.
  • Non Operating Income reached $232000.0 in Q4 2025 per RXRX's latest filing, down from $10.0 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $10.0 million in Q3 2025 to a low of -$11.3 million in Q1 2025.
  • Average Non Operating Income over 5 years is $1.9 million, with a median of $2.3 million recorded in 2022.
  • Peak YoY movement for Non Operating Income: soared 226800.0% in 2023, then tumbled 369.27% in 2025.
  • A 5-year view of Non Operating Income shows it stood at $27000.0 in 2021, then surged by 12825.93% to $3.5 million in 2022, then plummeted by 46.36% to $1.9 million in 2023, then skyrocketed by 160.1% to $4.9 million in 2024, then crashed by 95.24% to $232000.0 in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Non Operating Income are $232000.0 (Q4 2025), $10.0 million (Q3 2025), and $4.3 million (Q2 2025).